The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder

Aims: Four Phase 3 studies evaluated efficacy and safety of viloxazine extended‐release in the treatment of attention‐deficit/hyperactivity disorder (ADHD). The primary efficacy objective—change from baseline in ADHD Rating Scale‐5 (ADHD‐RS‐5) Total score at end of study (EOS)—was not met in one of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Azmi, Gomeni, Roberto, Wang, Zhao, Hull, Joseph T., Busse, Gregory D., Melyan, Zare, Fava, Maurizio, O'Neal, Welton, Rubin, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796605/
https://www.ncbi.nlm.nih.gov/pubmed/35588245
http://dx.doi.org/10.1111/bcp.15412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796605/
https://www.ncbi.nlm.nih.gov/pubmed/35588245
http://dx.doi.org/10.1111/bcp.15412

Ejemplares similares